Trials / Completed
CompletedNCT00542308
Zalutumumab in Non-curable Patients With SCCHN
An Open Label Single Arm Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination With Best Supportive Care, in Patients With Non-Curable Squamous Cell Carcinoma of the Head and Neck Who Have Failed Standard Platinum-based Chemotherapy.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Genmab · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Treatment, In combination with BSC, Open-label, Single arm, Efficacy Study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zalutumumab | Individual dose titration weekly i.v. doses |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2011-08-01
- Completion
- 2011-08-01
- First posted
- 2007-10-11
- Last updated
- 2023-08-03
- Results posted
- 2014-08-27
Locations
48 sites across 11 countries: United States, Austria, Chile, Colombia, Czechia, Germany, Israel, Italy, Peru, Portugal, Slovakia
Source: ClinicalTrials.gov record NCT00542308. Inclusion in this directory is not an endorsement.